Assertio Therapeutics, Inc. (ASRT) Analysts See $-0.17 EPS

October 13, 2018 - By olga

Analysts expect Assertio Therapeutics, Inc. (NASDAQ:ASRT) to report $-0.17 EPS on November, 6.They anticipate $0.08 EPS change or 32.00 % from last quarter’s $-0.25 EPS. After having $-0.33 EPS previously, Assertio Therapeutics, Inc.’s analysts see -48.48 % EPS growth. The stock increased 2.41% or $0.13 during the last trading session, reaching $5.52. About 305,798 shares traded. Assertio Therapeutics, Inc. (NASDAQ:ASRT) has declined 9.24% since October 13, 2017 and is downtrending. It has underperformed by 24.86% the S&P500.

Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. The company has market cap of $352.82 million. It offers Gralise , an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. It currently has negative earnings. The firm also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>